
Opinion|Videos|August 13, 2026
Second-Line NCCN Options and Approach to Progression
Author(s)Sandip Patel, MD, Chul Kim, MD
The segment introduces second-line sequencing, reviewing NCCN preferred options after frontline therapy.
Advertisement
Episodes in this series
The segment introduces second-line sequencing, reviewing NCCN preferred options after frontline therapy.This segment reviews a FLAURA2 exploratory analysis on chemotherapy rechallenge and outlines a practical approach to progression. The discussion then addresses how the chemotherapy-free interval influences the decision to rechallenge with platinum/pemetrexed versus moving to an amivantamab-based regimen or datopotamab deruxtecan. The segment closes by differentiating between datopotamab deruxtecan and amivantamab plus chemotherapy in the subsequent-line setting, citing TROPION-Lung01 and TROPION-Lung05 data.
Advertisement
Related to this article

Serial amino acid PET flagged responses earlier than MRI in IDH-mutant glioma treated with vorasidenib, interim data show.

Longer mirdametinib treatment increased confirmed and deep responses as treatment-related adverse effects declined in neurofibromatosis type 1 tumors.

Patrick Forde, MD, MBBCh, details how chemoimmunotherapy, pathologic response, and targeted therapy are reshaping resectable NSCLC care.

Long-term data show that plixorafenib yielded durable responses and no cumulative adverse effects in BRAF-altered primary central nervous system tumors.

The FDA approved durvalumab plus enfortumab vedotin for cisplatin-ineligible muscle-invasive bladder cancer.

The filing is supported by phase 3 REZILIENT3 data showing a median PFS of 14.5 vs 8.5 months with zipalertinib plus chemotherapy vs chemotherapy.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Durvalumab Plus Enfortumab Vedotin for Cisplatin-Ineligible MIBC
2
Dr Gleave on Selecting Patients for Perioperative Therapy in High-Risk Prostate Cancer
3
Dr Calais on Individualizing PSMA-Targeted Therapy Sequencing in Prostate Cancer
4
CHMP Recommends Approval of Belzutifan Plus Lenvatinib for Advanced ccRCC After PD-(L)1 Inhibition
5


